ACROBIOSYSTEMS CO.,LTD. — Investor Relations & Filings
ACROBIOSYSTEMS CO.,LTD. is a global biotechnology company specializing in the development and manufacturing of high-quality recombinant proteins and critical reagents for the life sciences industry. The company provides a comprehensive portfolio of products designed to accelerate the development of target therapeutics, including antibodies, cell and gene therapies, and vaccines. Key offerings include a wide range of biotinylated proteins, enzymes, and assay kits characterized by high bioactivity and batch-to-batch consistency. ACROBIOSYSTEMS supports drug discovery and clinical development through specialized platforms for protein engineering and characterization. Its products serve a diverse client base of pharmaceutical companies, biotechnology firms, and academic research institutions worldwide, focusing on therapeutic areas such as oncology, immunology, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于取得金融机构股票回购贷款承诺函的公告 | 2025-01-02 | Chinese | |
| 关于回购公司股份的进展公告 | 2025-01-02 | Chinese | |
| 关于2023年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告 | 2024-12-30 | Chinese | |
| 关于2024年前三季度利润分配预案的公告 | 2024-12-30 | Chinese | |
| 第二届董事会第十三次会议决议公告 | 2024-12-30 | Chinese | |
| 关于召开2025年第一次临时股东大会的通知 | 2024-12-30 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
2 filings
| |||||
| 44579089 | 关于取得金融机构股票回购贷款承诺函的公告 | 2025-01-02 | Chinese | ||
| 44579082 | 关于回购公司股份的进展公告 | 2025-01-02 | Chinese | ||
|
2024
13 filings
| |||||
| 44579077 | 关于2023年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市的公告 | 2024-12-30 | Chinese | ||
| 44579071 | 关于2024年前三季度利润分配预案的公告 | 2024-12-30 | Chinese | ||
| 44579065 | 第二届董事会第十三次会议决议公告 | 2024-12-30 | Chinese | ||
| 44579060 | 关于召开2025年第一次临时股东大会的通知 | 2024-12-30 | Chinese | ||
| 44579052 | 第二届监事会第十三次会议决议公告 | 2024-12-30 | Chinese | ||
| 44579042 | 第二届董事会第十二次会议决议公告 | 2024-12-10 | Chinese | ||
| 44579032 | 关于2023年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告 | 2024-12-10 | Chinese | ||
| 44579021 | 上海市通力律师事务所关于北京百普赛斯生物科技股份有限公司2023年限制性股票激励计划首次授予部分第一个归属期归属条件成就及作废部分已授予但尚未归属的限制性股票事项的法律意见书 | 2024-12-10 | Chinese | ||
| 44578984 | 2024年第二次临时股东大会决议公告 | 2024-12-10 | Chinese | ||
| 44578973 | 第二届监事会第十二次会议决议公告 | 2024-12-10 | Chinese | ||
| 44578968 | 上海市通力律师事务所关于北京百普赛斯生物科技股份有限公司2024年第二次临时股东大会的法律意见书 | 2024-12-10 | Chinese | ||
| 44578960 | 监事会关于公司2023年限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见 | 2024-12-10 | Chinese | ||
| 44578951 | 关于作废部分已授予但尚未归属的限制性股票的公告 | 2024-12-10 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ACROBIOSYSTEMS CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56034/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56034 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56034 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56034 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56034}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ACROBIOSYSTEMS CO.,LTD. (id: 56034)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.